CA3103175A1 - Microrna inhibitors for use in treating metabolic diseases - Google Patents
Microrna inhibitors for use in treating metabolic diseases Download PDFInfo
- Publication number
- CA3103175A1 CA3103175A1 CA3103175A CA3103175A CA3103175A1 CA 3103175 A1 CA3103175 A1 CA 3103175A1 CA 3103175 A CA3103175 A CA 3103175A CA 3103175 A CA3103175 A CA 3103175A CA 3103175 A1 CA3103175 A1 CA 3103175A1
- Authority
- CA
- Canada
- Prior art keywords
- mir
- inhibitor
- fragment
- composition
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU100927 | 2018-09-11 | ||
| LULU100927 | 2018-09-11 | ||
| PCT/EP2019/074056 WO2020053186A1 (en) | 2018-09-11 | 2019-09-10 | Microrna inhibitors for use in treating metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3103175A1 true CA3103175A1 (en) | 2020-03-19 |
Family
ID=63998726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3103175A Pending CA3103175A1 (en) | 2018-09-11 | 2019-09-10 | Microrna inhibitors for use in treating metabolic diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12584126B2 (https=) |
| EP (1) | EP3850099B1 (https=) |
| JP (2) | JP7530836B2 (https=) |
| CN (1) | CN112654705B (https=) |
| CA (1) | CA3103175A1 (https=) |
| DK (1) | DK3850099T3 (https=) |
| WO (1) | WO2020053186A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12584126B2 (en) | 2018-09-11 | 2026-03-24 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | microRNA inhibitors for use in treating metabolic diseases |
| CN111228291B (zh) * | 2020-03-20 | 2020-10-02 | 军事科学院军事医学研究院环境医学与作业医学研究所 | miR-541在制备抗神经元细胞缺氧损伤药物中的应用及药物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| WO2014074874A1 (en) * | 2012-11-09 | 2014-05-15 | Regents Of The University Of Minnesota | Osteosarcoma diagnostic and prognostic methods |
| EP2868746A1 (en) | 2013-10-29 | 2015-05-06 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Micrornas modulating the effect of glucocorticoid signaling |
| AU2015335923B2 (en) * | 2014-10-21 | 2021-04-29 | University Of Massachusetts | Recombinant AAV variants and uses thereof |
| CN106267207A (zh) * | 2015-06-05 | 2017-01-04 | 昆山彭济凯丰生物科技有限公司 | 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用 |
| CN119033819A (zh) * | 2017-11-22 | 2024-11-29 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| US12584126B2 (en) | 2018-09-11 | 2026-03-24 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | microRNA inhibitors for use in treating metabolic diseases |
-
2019
- 2019-09-10 US US17/251,803 patent/US12584126B2/en active Active
- 2019-09-10 CN CN201980058818.XA patent/CN112654705B/zh active Active
- 2019-09-10 JP JP2020569736A patent/JP7530836B2/ja active Active
- 2019-09-10 CA CA3103175A patent/CA3103175A1/en active Pending
- 2019-09-10 WO PCT/EP2019/074056 patent/WO2020053186A1/en not_active Ceased
- 2019-09-10 EP EP19780152.5A patent/EP3850099B1/en active Active
- 2019-09-10 DK DK19780152.5T patent/DK3850099T3/da active
-
2024
- 2024-03-12 JP JP2024037853A patent/JP2024073525A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7530836B2 (ja) | 2024-08-08 |
| US12584126B2 (en) | 2026-03-24 |
| EP3850099A1 (en) | 2021-07-21 |
| CN112654705A (zh) | 2021-04-13 |
| JP2024073525A (ja) | 2024-05-29 |
| JP2021535079A (ja) | 2021-12-16 |
| WO2020053186A1 (en) | 2020-03-19 |
| EP3850099B1 (en) | 2025-09-03 |
| US20210254067A1 (en) | 2021-08-19 |
| DK3850099T3 (da) | 2025-10-13 |
| CN112654705B (zh) | 2024-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012322788B2 (en) | Micrornas in neurodegenerative disorders | |
| EP3354734B1 (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif | |
| EP2208499A1 (en) | Nucleic acid capable of regulating the proliferation of cell | |
| JP2024073525A (ja) | 代謝性疾患の処置において使用するためのマイクロｒｎａインヒビター | |
| EP2298359A1 (en) | Nucleic acid capable of controlling degranulation of mast cell | |
| EP2683411B1 (en) | Methods of using microrna-26a to promote angiogenesis | |
| WO2010120969A1 (en) | Targeting of the mir-30 family and let-7 family as a treatment for heart disease | |
| US20090136957A1 (en) | Methods and compositions for regulating cell cycle progression via the miR-106B family | |
| Tan et al. | MicroRNA-based therapy in pain medicine: Current progress and future prospects | |
| CA3133704A1 (en) | Rna editing inhibitors and methods of use | |
| KR20150036140A (ko) | 마이크로RNAs의 MIR-15 패밀리의 억제제 | |
| WO2016049512A1 (en) | Rna-modulating agents | |
| Durso et al. | Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells | |
| US20090023670A1 (en) | Regulation of Transgene Expression by RNA Interference | |
| JP2009516710A (ja) | ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート | |
| EP2175023A1 (en) | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA | |
| CN120905229B (zh) | 一种靶向INHBE基因表达的siRNA及其缀合物和用途 | |
| JP7530106B2 (ja) | Ｉｈｈ発現を調節するための核酸複合体 | |
| WO2017096053A2 (en) | Methods of reducing expression of x-inactivation escapee genes and autosomal genes | |
| WO2025195381A1 (zh) | 一种靶向INHBE基因表达的siRNA及其缀合物和用途 | |
| WO2012142199A1 (en) | Mirnas dysregulated in ewing sarcoma | |
| WO2011010737A1 (ja) | マイクロｒｎａ切断用のガイド核酸 | |
| WO2021039598A1 (ja) | Ｒｎａ作用抑制剤及びその利用 | |
| EP4017505A1 (en) | Method of modulating adiposity | |
| Soukup et al. | MicroRNA-513 Regulates B7-H1 Translation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240828 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250901 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250901 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260113 |